CanSino Biologics Inc. (CanSinoBIO, SHSE: 688185, HKEX:06185) is an innovative biopharmaceutical company dedicated to exploring best solutions to the prevention of diseases through cutting-edge research & development, advanced manufacturing and commercialization of innovative vaccine products for human use worldwide.
Since its establishment in Tianjin, China in 2009, CanSinoBIO has experienced tremendous growth with 17 vaccines preventing 12 diseases, including approved vaccines for Ebola virus disease (Ad5-EBOV), COVID-19 (Ad5-nCoV, trade name: Convidecia), and meningitis (MCV2, trade name: Menphecia). CanSinoBIO has been listed on the Main Board of Hong Kong Exchange and Clearing Limited (HKEx) in March 2019. A year later, CanSinoBIO has successfully listed on the Sci-Tech Innovation Board (STAR Market) of the Shanghai Stock Exchange, making it the first "A+H" dual listing vaccine company. CanSinoBIO is focusing on continually expanding manufacturing capacity for its current vaccine candidates and further enhancing the competitiveness and the scope of its portfolio by promoting the R&D of new vaccine candidates.
Leveraging broad experiences of our accomplished team of scientists and business leaders who had previously held technical and senior management positions at many of the leading pharmaceutical companies in the world, including Sanofi Pasteur, Astra Zeneca, Wyeth (now Pfizer) and CNBG (China), CanSinoBIO has developed five key platform technologies, including adenovirus-based viral vector vaccine, synthetic biotechnology, protein structure design and recombination vaccine formulation technologies as well as mRNA technologies.
In addition, the company has in-licensed a number of new technologies and intellectual properties through collaborations with international research organizations and biotechnology companies. CanSinoBIO collaborates through partnerships with world-class academic centers or start-up companies that develop innovative technologies, to prepare the portfolio of the next decades and ensure sustainable growth of the company.
CanSinoBIO has developed pipelines of 17 vaccine candidates for 12 infectious diseases, preventing meningitis, pneumonia, tuberculosis, COVID-19, Ebola virus disease, pertussis, diphtheria, tetanus, shingles etc. Among these, the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Convidecia was approved by NMPA of China, making it the first of its kind authorized in China. Ad5-EBOV, the globally innovative Ebola virus disease vaccine, has received NDA (New Drug Application) approval in China in October 2017. The Group A and Group C Meningococcal Conjugate Vaccine (CRM197) (MCV2) Menphecia was approved by NMPA of China in June, 2021. At present, CanSinoBIO has six vaccine candidates in the clinical trial stage or new drug application stage. There are also seven preclinical vaccine candidates under development, including one combination vaccine candidate.
CanSinoBIO’s current R&D Center and manufacturing facilities are designed, qualified and operated according to international cGMP standards (FDA, EU, WHO and China), capable of supporting the commercialization of our vaccine products. In addition, CanSinoBIO's Recombinant Novel Coronavirus Vaccine, Convidecia has been issued a Good Manufacturing Practice (GMP) certificate by the Hungarian National Institute of Pharmacy and Nutrition (OGYÉI), recognizing that CanSinoBIO’s manufacturing facilities and quality control system comply with the high production standards and guidelines required by the European Union. Moreover, the GMP pilot plants located in the R&D Center have passed EU QPs’ audits.
Vaccination is an essential part of effective disease control and prevention. CanSinoBIO is committed to make innovative and high quality vaccines accessible to people all over the world thus empower people to pursue healthy and better life.